AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2018
Mar 27, 2018
34891_dirs_2018-03-27_795a09af-f7a7-4aa0-b90d-f723017c405a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27
Reporting Person: Smith W Bradford (CFO, Treasurer & Secretary)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option | $0.64 | 2027-04-05 | Common Stock (163404) | Direct | |
| Employee Stock Option | $6.64 | 2027-12-07 | Common Stock (63497) | Direct |
Footnotes
F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017.
F2: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018.
More from Q32 Bio Inc.
Capital/Financing Update
2026
May 27
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Capital/Financing Update
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27